Boehringer, VTU Technology sign technology, marketing collaboration agreement

As per the terms of the non-exclusive agreement, Boehringer Ingelheim will have access to VTU Technology’s ready-to-use high expression Pichia system in close collaboration with the VTU team for the development and manufacture of therapeutic proteins.

The collaboration agreement is set up to provide the partners’ customers with a broader range of contract services.

The integrated concept offers customers access to Boehringer’s clinical and commercial manufacturing technology along with VTU Technology’s competence in high-expression technologies and speed in strain development.

Boehringer Biopharmaceuticals Division senior vice president Rolf Werner said that VTU Technology is well positioned to play an important role as a partner in our collaboration.

"This collaboration will bring Pichia technology offering us great value and further flexibility in our contract manufacturing business, while complementing our existing scaffold technology platforms," Werner said.

VTU Technology founder and CEO Michael Koncar said that they were proud to have established this agreement with Boehringer Ingelheim.

"This collaboration represents an important element of VTU Technology’s strategy while reflecting the potential and attractiveness of our expression technology for efficient manufacture of biopharmaceuticals," Koncar said.

"We are convinced that through this new marketing and technology alliance both companies can look forward to a continued growth of their customer base and in-house contract development business."